CNS Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
CNSP$3.94+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements and Supplementary Data
| Item 8. | Financial Statements and Supplementary Data. |
|---|
Index to Financial Statements
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 206) | 42 |
| Balance Sheets as of December 31, 2024 and 2023 | 43 |
| Statements of Operations for the years ended December 31, 2024 and 2023 | 44 |
| Statements of Stockholders’ Equity (Deficit) for the years ended December 31, 2024 and 2023 | 45 |
| Statements of Cash Flows for the years ended December 31, 2024 and 2023 | 46 |
| Notes to Financial Statements | 47 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.